Written by Steven Hansen
The U.S. new cases 7-day rolling average are 9.8 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 3.5 % HIGHER than the rolling average one week ago. Today’s posts include:
- U.S. Coronavirus New Cases are 49,930
- U.S. Coronavirus deaths are at 738
- U.S. Coronavirus immunizations have been administered to 73.4 doses per 100 people.
- The 7-day rolling average rate of growth of the pandemic shows new cases worsened and deaths worsened
- Report of Adverse Events Related to the Corona Vaccine, April 2021: Never has a vaccine injured so many
- Yes, America can still beat the coronavirus – don’t buy the panic stories
- Next Generation of Covid-19 Vaccines Could Be Pill or Spray
- Children Now Account For 22% Of New U.S. COVID Cases
- Fever Didn’t Drive Many Americans to Get a COVID Test
- Pandemic worsened older adults’ mental health & sleep; others show long-term resilience
- Evidence that elevated blood glucose is a significant risk factor for severe COVID-19
- Experimental Antibody Drug Neutralizes COVID-19 Variants
- No Link Seen Between COVID-19 and Aspirin or Ibuprofen
include($_SERVER[‘DOCUMENT_ROOT’].’/pages/coronavirus1.htm’); ?>
Hospitalizations Are The Only Accurate Gauge
Hospitalizations historically appear to be little affected by weekends or holidays. The hospitalization growth rate trend continues to improve.
source: https://gis.cdc.gov/grasp/covidnet/COVID19_3.html
Historically, hospitalization growth follows new case growth by one to two weeks.
As an analyst, I use the rate of growth to determine the trend. But, the size of the pandemic is growing in terms of real numbers – and if the rate of growth does not become negative – the pandemic will overwhelm all resources.
The graph below shows the rate of growth relative to the growth a week earlier updated through today [note that negative numbers mean the rolling averages are LOWER than the rolling averages one week ago]. As one can see, the rate of growth for new cases peaked in early December 2020 for Thanksgiving, and early January 2021 for end-of-year holidays – and it now shows that the coronavirus effect is improving.
In the scheme of things, new cases decline first, followed by hospitalizations, and then deaths. The potential fourth wave did not materialize likely due to immunizations.
Coronavirus News You May Have Missed
Children Now Account For 22% Of New U.S. COVID Cases. – NPR
The number of children contracting COVID-19 in the U.S. is much lower than the record highs set at the start of the new year, but children now account for more than a fifth of new coronavirus cases in states that release data by age, according to the American Academy of Pediatrics. It’s a statistic that may surprise many: Just one year ago, child COVID-19 cases made up only around 3% of the U.S. total.
On Monday, the AAP said children represented 22.4% of new cases reported in the past week, accounting for 71,649 out of 319,601 cases. The latest report, drawn from data collected through April 29, illustrates how children’s share of coronavirus infections has grown in recent weeks.
Experts link the trend to several factors – particularly high vaccination rates among older Americans. The U.S. recently announced 100 million people were fully vaccinated against COVID-19. But other dynamics are also in play, from new COVID-19 variants to the loosening of restrictions on school activities.
It’s also worth noting that for the vast majority of the pandemic, the age group with the highest case rates has been 18 to 24 in the U.S., as the Centers for Disease Control and Prevention notes.
Next Generation of Covid-19 Vaccines Could Be Pill or Spray – Wall Street Journal
The next generation of Covid-19 vaccines in development could come as a pill or a nasal spray and be easier to store and transport than the current handful of shots that form the backbone of the world-wide vaccination effort.
These newer vaccines, from U.S. government labs and companies including Sanofi SA, Altimmune Inc. and Gritstone Oncology Inc., also have the potential to provide longer-lasting immune responses and be more potent against newer and multiple viral variants, possibly helping to head off future pandemics, the companies say.
Vaccines currently authorized for use in the U.S. from Pfizer Inc. and its partner BioNTech SE, as well as Moderna Inc., must be transported and stored at low temperatures and require two doses administered weeks apart.
New vaccines could “constitute some improvement” over those limitations and more easily accommodate vaccination efforts in rural areas, said Gregory Poland, professor and vaccine researcher at the Mayo Clinic in Rochester, Minn. “You will see second-generation, third-generation vaccines,” he said.
There are 277 Covid-19 vaccines in development globally, of which 93 have entered human testing, according to the World Health Organization. Most of the vaccines in clinical testing are injected, but there are two oral formulations and seven nasal-spray formulations.
Fever Didn’t Drive Many Americans to Get a COVID Test – MedPage
Although fever is one of the classic symptoms of early COVID-19, most participants reporting febrile episodes in a large panel survey didn’t get tested for the illness, researchers said.
Only 17% of people in the COVID-19 Citizen Science Study who self-reported temperatures higher than 38.0°C (100.4°F) at some point said they had been tested — and nearly one-third of those hadn’t received results within 2 weeks, according to Mark J. Pletcher, MD, MPH, of the University of California San Francisco (UCSF), and colleagues.
A statistical model bumped up that figure somewhat, with an estimated probability for receiving a coronavirus test result within 7 days of 20.5% (95% CI 19.1%-22.0%), reaching 26% by the end of 2 weeks (95% CI not given).
Black participants may have been even less likely to be tested, with an adjusted hazard ratio of 0.59 relative to non-Black/non-Hispanic participants, but this value was not statistically significant, the researchers reported in JAMA Network Open.
The data were based on a total of 3,865 febrile episodes reported by 2,679 participants.
“This cohort study’s results suggest systematic underuse of coronavirus testing in patients with febrile illness,” Pletcher and colleagues concluded. The findings also could explain why COVID-19 became a much bigger problem for the U.S. than it did in “countries such as China and South Korea,” which pursued “a much more aggressive targeted approach to testing and appear to have substantially lower community transmission rates,” the researchers wrote.
But why were rates in the Citizen Science Study so low? That remains a mystery.
“Whether this is because of lack of testing availability, knowledge about how to get a test, understanding about the importance of testing, or active avoidance (e.g., to avoid economic hardships associated with isolation and quarantine of contacts if one tests positive) is unclear,” Pletcher and co-authors wrote.
Report of Adverse Events Related to the Corona Vaccine, April 2021: Never has a vaccine injured so many. – The Israeli People’s Committee
[editor’s note: I have validated this as far as I can as this group seems to have an anti-vax bent – but that does not make what they are saying false]
Here are our main findings:
- We received 288 reports of deaths occurring in proximity to the vaccination (90% up to 10 days after the vaccination). 64% are men. According to the Ministry of Health’s figures: only 45 deaths occurred in proximity to the vaccination.
- According to data from the Central Bureau of Statistics (CBS), during January-February 2021, in the midst of the vaccination operation, there was a 22% increase in overall mortality in Israel compared to the bi-monthly average mortality in the previous year. In fact, the period of January-February 2021 is the deadliest one in the last decade, with the highest overall mortality rates, when compared to the corresponding months over the last 10 years.
- Among the age group of 20-29, the increase in overall mortality rate is even more dramatic. In this group, during the same vaccination period, January-February 2021, there has been a 32% increase in overall mortality compared to the bi-monthly average mortality in 2020.
- A statistical analysis of data from the CBS combined with information from the Ministry of Health leads to the conclusion that the mortality rate amongst the vaccinated is estimated at 1:5,000 (1:13,000 for ages 20-49, 1:6,000 for ages 50-69, 1:1600 for ages 70+). According to this assessment, it is possible to estimate that the number of deaths in Israel that have occurred in proximity to the vaccination, currently stands at about 1,000-1,100 people.
- There is a high correlation between the number of people vaccinated per day and the number of deaths per day, in the range of up to 10 days post vaccination in all age groups. For ages 20-49 – a range of 9 days from the date of vaccination to death; for ages 50-69 – 5 days from the date of vaccination to death; for ages 70 and up – 3 days from the date of vaccination to death.
- The risk of death after the second vaccination is higher than the risk of death after the first vaccination.
- Up until the publication date of this report, a total of 2,066 reports of adverse events have been recorded by The Israeli People`s Committee and the figures continue to flow in. These reports indicate damage to almost every system in the human body. These figures also highlight the inconceivable gap between official Israeli media reports and what is actually happening, enabling a “two worlds” situation due to journalistic failure to sense, identify and report on what is actually happening in citizens` real-life. [editor’s note: their finds go on]
Yes, America can still beat the coronavirus — don’t buy the panic stories – New York Times
Don’t freak out over the New York Times story Monday claiming that the expert consensus now is that the United States will probably never reach herd immunity from the coronavirus.
Herd immunity is a handy concept but also a slippery one. And the key point is simply to get the country, and eventually the world, to a near-zero transmission rate — and progress toward that goal continues by leaps and bounds. Beyond that, it’s a guessing game, with expert guesses still merely guesses.
Yes, the rise of virus variants complicates the picture. But most fears here are overhyped: The vaccines still provide major resistance to new forms of the bug. And science suggests that even if variants are more contagious, they’re also likely to be less deadly.
As for Americas’ slowing vaccination rates: That’s a challenge that leadership can overcome.
Herd immunity has always been a moving target: Dr. Anthony Fauci has admitted to changing his stated threshold based on not science but public opinion. “When polls said only about half of all Americans would take a vaccine, I was saying herd immunity would take 70 to 75 percent,” he told the Times. “Then, when newer surveys said 60 percent or more would take it, I thought, ‘I can nudge this up a bit,’ so I went to 80, 85.”
Fauci is one expert the Times quotes to claim a scientific consensus. But others disagree. Marty Makary of the Johns Hopkins School of Medicine, for one, notes that the Times’ piece “dismisses natural immunity.” More than half of the unvaccinated could have natural immunity from getting COVID, as not all cases were tested and recorded — or even, in the case of the asymptomatic, known.
Pandemic worsened older adults’ mental health & sleep; others show long-term resilience – EurekAlert
Nearly one in five older adults say their mental health has gotten worse since the pandemic began in March 2020, and an equal percentage say their sleep has suffered in that time too. More than one in four say they’re more anxious or worried than before the COVID-19 era, according to a new poll of people age 50 to 80.
Women, people in their 50s and early 60s, and older adults who have a college degree or higher were more likely than others to report worse mental health than before the pandemic, according to the new findings from the National Poll on Healthy Aging. Older adults who say their physical health is fair or poor were most likely to report worse mental health, with 24% saying this.
And when asked about the last two weeks before they were surveyed, the percent who said they had concerning mental health symptoms was even higher, with 28% saying they felt depressed or hopeless in that time, 34% saying they’d been nervous or anxious, and 44% saying they’d recently felt stressed.
Just under two-thirds (64%) said they had had trouble falling asleep or staying asleep at least once in the past week, twice the percentage who said this in a 2017 poll of a similar group of older adults.
The poll is based at the University of Michigan’s Institute for Healthcare Policy and Innovation and receives support from AARP and Michigan Medicine, U-M’s academic medical center. It draws from the answers of a national sample of more than 2,000 adults aged 50 to 80 to a poll in late January, when COVID-19 case rates were high across the nation and vaccination of older adults had just begun.
Evidence that elevated blood glucose is a significant risk factor for severe COVID-19 – News-Medical
Researchers from Switzerland recently developed machine learning models to help mine 240,000 scientific papers in the CORD-19 database. Using the models, they constructed knowledge graphs to analyze the extracted data and search for a potential reason for disease severity. The study is published on the preprint server, medRxiv*.
The literature analysis pointed to elevated blood glucose levels as a leading facilitator in the progression of COVID-19. Evidence linking elevated glucose to various steps in the life cycle of the virus and presentation of COVID-19 symptoms were also found.
The observations suggested that blood glucose elevation provided ideal conditions for SARS-CoV-2 to attack the lung’s immune defense system and gain access to alveolar cells before binding to the human ACE2 receptor. High glucose levels also enabled the entry of the virus to the pulmonary cells and rapid viral replication within cells and induced a pulmonary inflammatory response. This massive immune response overwhelms an already weakened immune system and triggers a series of events causing systemic inflammation, cell damage, and the release of cytokines.
The researchers analyzed data across the papers, reconstructed the virus at the pulmonary airway surface, and then performed quantitative computational modeling of the impact of glucose levels on the infection process. They concluded that glucose level elevation could facilitate COVID-19 progression through multiple mechanisms. This explains the variation in disease severity across the population.
No Link Seen Between COVID-19 and Aspirin or Ibuprofen – Reuters
A large new study found no indication that use of non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin or ibuprofen increases people’s vulnerability to infection by the new coronavirus.
Because early reports had suggested such a link, researchers used the COVID Symptom Study smartphone app to query more than 2.7 million individuals in the United States, the UK and Sweden about their use of aspirin and other NSAIDs, as well as about virus symptoms, COVID-19 testing, and healthcare seeking behavior.
Close to 9,000 participants reported a positive COVID-19 test during the study, according to a report posted on medRxiv in advance of peer review.
After accounting for individuals’ lifestyle factors, other illnesses, and symptoms, regular use of NSAIDs was not associated with a higher risk of becoming infected with the coronavirus.
“There have been lingering concerns” that commonly used NSAIDs “could increase the risk of COVID infection or worsen the disease course among those who acquire the infection,” coauthor Dr. Andrew Chan of the Massachusetts General Hospital in Boston told Reuters.
“Our study shows that there is no such an association and initial concerns were probably due to the fact that individuals with other risk factors for COVID or symptoms of COVID were more likely to take NSAIDs, rather than a cause and effect relationship,” he said.
Experimental Antibody Drug Neutralizes COVID-19 Variants – Medscape
An experimental monoclonal antibody treatment for COVID-19 being developed by Eli Lilly and Co and AbCellera Biologics Inc can “potently” neutralize numerous coronavirus variants, including those first identified in the UK, Brazil, South Africa, California and New York, scientists have found in test tube experiments.
The antibody – known as LY-CoV1404 or LY3853113 – works by attaching itself to a highly conserved epitope on the virus’s receptor binding domain, which means the drug is likely to retain its effectiveness over time, the researchers said in a report posted on bioRxiv ahead of peer review.
“New variant-resistant treatments such as LY-CoV1404 are desperately needed, given that some of the existing therapeutic antibodies are less effective or ineffective against certain variants and the impact of variants on vaccine efficacy is still poorly understood,” the research team wrote.
An AbCellera spokesperson said the company plans to release information about tests of the drug in humans on Tuesday.
Yellen says interest rates may need to increase – The Hill
Treasury Secretary Janet Yellen on Tuesday said that interest rates may need to increase to keep the recovering economy from going into overdrive on the heels of significant government spending.
“It may be that interest rates will have to rise somewhat to make sure that our economy doesn’t overheat, even though the additional spending is relatively small relative to the size of the economy,” she said in response to a question posed by The Atlantic about whether the economy could absorb the large dose of spending President Biden was proposing.
Critics of the major spending push have warned that it will push up prices, as government funds boost demand faster than production of supply can keep up.
Were inflation to take hold in a serious way, it would erode purchasing power, particularly for low earners, and could require interest rate hikes to get inflation back in line. An increase in interest rates could slow or even reverse the economic recovery.
Federal Reserve Chairman Jerome Powell has said that the recent uptick in prices is likely to be temporary and that he doesn’t expect interest rates to rise this year, but that the central bank is closely monitoring inflation.
Stock markets, which have in recent months sunk on signs of higher inflation and concerns about rising interest rates, did not react significantly to Yellen’s comments, which may have referred to market borrowing rates as opposed to the base rate set by the federal reserve.
- High-risk groups such as the elderly and people with underlying medical conditions are expected to be the first in line to get Covid vaccine booster shots, a Pfizer executive told investors Tuesday.
- Executives at Pfizer and BioNTech previously said people will likely need a booster shot, or third dose, within 12 months of getting fully vaccinated. They also said it’s likely people will need to get additional shots each year.
- During an earnings call Tuesday, Mikael Dolsten, Pfizer’s chief scientific officer, said it makes sense to start with those most susceptible to severe illness.
Pfizer seeking authorization for Covid-19 vaccine to be stored at standard refrigerator temperatures – CNN
Pfizer has submitted information to the US Food and Drug Administration that may allow its Covid-19 vaccine to be stored at standard refrigerator temperatures, the company’s CEO said Tuesday. Such a change could help simplify distribution of the vaccine.
Pfizer CEO Albert Bourla said in an earnings meeting on Tuesday the company submitted new data to the FDA on Friday, and it may “soon” have an emergency use authorization to allow standard refrigeration for up to four weeks.
Currently, Pfizer’s vaccine is authorized to be stored at ultra-cold temperatures, between -80 and -60 degrees Celsius, or in cold storage, between -25 and -15 degrees Celsius, for a maximum of two weeks, which can complicate distribution of the vaccine.
According to Bourla, new data could allow the vaccine to be stored at standard temperatures, between 2 and 8 degrees Celsius, for up to four weeks.
Bourla said Pfizer is working on additional formulations that could further extend the storage time of the vaccine in both standard and ultra-cold refrigerators.
The following are foreign headlines with hyperlinks to the posts
India’s COVID-19 vaccine, Covaxin, was effective against three key variants, those originating in the U.K., Brazil, and India
At least 10 people died after a hospital in India ran out of oxygen.
Eight lions test positive for Covid-19 at an Indian zoo
Covid in Varanasi: Anger rises as coronavirus rages in Modi’s constituency
Thanks, COVID-19: Germany cancels Oktoberfest again
Venezuela to Begin Clinical Trials of Cuba’s Abdala Vaccine Candidate
India Crosses 20 Million COVID-19 Cases As Critical Shortages Worsen
India will be past peak “possibly even within days,” top scientist says
Singapore extends quarantine to 21 days for most travelers
Australia Aiming to Begin India Repatriation Flights Next Week After Ban. The government imposed a strict lockdown on flights from India last week, stranding some 8,000 citizens overseas as India faces soaring coronavirus cases and deaths.
Hong Kong backtracks on a plan to require vaccinations for domestic workers.
US providing more than $100 million worth of aid to India, embassy says
EU drugs regulator begins review of China’s Sinovac Covid-19 vaccine
The United Kingdom is hosting the first face-to-face G7 gathering in two years
Covid-19 caused one in three deaths in Brazil so far this year
The following additional national and state headlines with hyperlinks to the posts
White House plans to redistribute unordered vaccine supply, telling states: Use it or lose it
The F.D.A. plans to authorize Pfizer’s Covid vaccine for adolescents 12 to 15 by early next week.
Pfizer plans to seek full approval of its vaccine by the end of the month.
Pfizer says it will seek clearance in September for its vaccine to be used in children aged 2 to 11.
Pfizer expects to produce at least 3 billion Covid-19 vaccine doses next year
President Joe Biden says he wants 70% of U.S. adults to receive at least one COVID-19 shot by July 4. Today, about 56% of adults have received at least one shot.
US sets pandemic-era high for air travel, over 1.6 million
HEPA filter effectively reduces airborne respiratory particles generated during vigorous exercise
COVID-19 Antibodies Still Detectable at 12 Months
Pfizer earned $3.5 billion on COVID-19 vaccine in first quarter
As vaccinations slow, at least 22 states not ordering their full allotment
Biden’s New Goal: At Least One COVID Vaccine Shot for 70% of Adults by 7/4
DeSantis Mask Order Leads Disney to Evaluate Regulations at Florida Parks
New cases are climbing in Arizona while most of the U.S. improves.
Today’s Posts On Econintersect Showing Impact Of The Pandemic With Hyperlinks
March 2021 Headline Manufacturing New Orders Improve
March 2021 Trade Data Improves
March 2021 CoreLogic Home Prices: Millennials Propel Home Buying
Warning to Readers
The amount of politically biased articles on the internet continues. And studies and opinions of the experts continue to contradict other studies and expert opinions. Honestly, it is difficult to believe anything anymore.
I assemble this coronavirus update daily – sifting through the posts on the internet. I try to avoid politically slanted posts (mostly from CNN, New York Times, and the Washington Post) and can usually find unslanted posts on that subject from other sources on the internet. I wait to publish posts on subjects that I cannot validate across several sources. But after all this extra work, I do not know if I have conveyed the REAL facts. It is my job to provide information so that you have the facts necessary – and then it is up to readers to draw conclusions.
Analyst Opinion of Coronavirus Data
There are several takeaways that need to be understood when viewing coronavirus statistical data:
- The global counts are suspect for a variety of reasons including political. Even the U.S. count has issues as it is possible that as much as half the population has had coronavirus and was asymptomatic. It would be a far better metric using a random sampling of the population weekly. In short, we do not understand the size of the error in the tracking numbers.
- Just because some of the methodology used in aggregating the data in the U.S. is flawed – as long as the flaw is uniformly applied – you establish a baseline. This is why it is dangerous to compare two countries as they likely use different methodologies to determine who has (and who died) from coronavirus.
- COVID-19 and the flu are different but can have similar symptoms. COVID-19 so far is much more deadly than the flu. [click here to compare symptoms]
- From an industrial engineering point of view, one can argue that it is best to flatten the curve only to the point that the health care system is barely able to cope. This solution only works if-and-only-if one can catch this coronavirus once and develops immunity. In the case of COVID-19, herd immunity may need to be in the 80% to 85% range. WHO warns that few have developed antibodies to COVID-19 when recovering from COVID-19. Herd immunity does not look like an option without immunization although there is now a discussion of whether T-Cells play a part in immunity [which means one might have immunity without antibodies]
- Older population countries will have a significantly higher death rate as there is relatively few hospitalizations and deaths in younger age groups..
- There are at least 8 strains of the coronavirus. California and New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States.
What we do or do not know about the coronavirus [actually there is little scientifically proven information]. Most of our knowledge is anecdotal, from studies with limited subjects, or from studies without peer review.
- How many people have been infected as many do not show symptoms?
- Masks do work. Unfortunately, early in the pandemic, many health experts — in the U.S. and around the world — decided that the public could not be trusted to hear the truth about masks. Instead, the experts spread a misleading message, discouraging the use of masks.
- Current thinking is that we develop at least 12 months of immunity from further COVID infection.
- The Moderna and Pfizer vaccines have an effectiveness rate of about 95 percent after two doses. That is on par with the vaccines for chickenpox and measles. The 95 percent number understates the effectiveness as it counts anyone who came down with a mild case of Covid-19 as a failure.
- To what degree do people who never develop symptoms contribute to transmission? Research early in the pandemic suggested that the rate of asymptomatic infections could be as high as 81%. But a meta-analysis, which included 13 studies involving 21,708 people, calculated the rate of asymptomatic presentation to be 17%.
- The accuracy of rapid testing is questioned – and the more accurate test results are not being given in a timely manner.
- Can children widely spread coronavirus? [current thinking is that they are a minor source of the pandemic spread]
- Why have some places avoided big coronavirus outbreaks – and others hit hard?
- Air conditioning contributes to the pandemic spread.
- It appears that there is increased risk of infection and mortality for those living in larger occupancy households.
- Male patients have almost three times the odds of requiring intensive treatment unit (ITU) admission compared to females.
- Outdoor activities seem to be a lower risk than indoor activities.
Treatments with solid scientific support:
- Dexamethasone
- Proning, or turning someone on their stomach
- Remdesivir
- Baricitinib
Treatments with potential but limited evidence:
- ECMO, or extracorporeal membrane oxygenation
- fluvoxamine
- Cyclosporine
- Famotidine
- Intravenous immunoglobulin
- Ivermectin
- Interferons
Drugs shown to be ineffective:
- The combination of lopinavir-ritonavir
- Hydroxychloroquine
- Insulin
- High dose zinc and vitamin C
- Convalescent plasma
- Monoclonal antibodies
- Tocilizumab
- Anti-coagulants
- A current scientific understanding of the way the coronavirus works can be found [here].
There is now a vaccine available – the questions remain:
- will there be any permanent side effects that will appear months from now,
- how long immunity will last [we can currently say we do not know if it will last more than 4 months],
- there is no solid evidence yet the vaccine will block transmission
Heavy breakouts of coronavirus have hit farmworkers. Farmworkers are essential to the food supply. They cannot shelter at home. Consider:
- they have high rates of respiratory disease [occupational hazard]
- they travel on crowded buses chartered by their employers
- few have health insurance
- they cannot social distance and live two to four to a room – and they eat together
- some reports say half are undocumented
- they are low paid and cannot afford not to work – so they will go to work sick
- they do not have access to sanitation when working
- a coronavirus outbreak among farmworkers can potentially shutter entire farm
The bottom line is that COVID-19 so far has been shown to be much more deadly than the data on the flu. Using CDC data, the flu has a mortality rate between 0.06 % and 0.11 % Vs. the coronavirus which to date has a mortality rate of 4 % [the 4% is the average of overall statistics – however in the last few months it has been hovering around 1.0%] – which makes it between 10 and 80 times more deadly. The reason for ranges:
Because influenza surveillance does not capture all cases of flu that occur in the U.S., CDC provides these estimated ranges to better reflect the larger burden of influenza.
There will be a commission set up after this pandemic ends to find fault [it is easy to find fault when a once-in-a-lifetime event occurs] and to produce recommendations for the next time a pandemic happens. Those that hate President Trump will conclude the virus is his fault.
Resources:
- Get the latest public health information from CDC: https://www.coronavirus.gov .
- Get the latest research from NIH: https://www.nih.gov/coronavirus.
- Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/.
- List of studies: https://icite.od.nih.gov/covid19/search/#search:searchId=5ee124ed70bb967c49672dad
include(“/home/aleta/public_html/files/ad_openx.htm”); ?>